MedPath

Mycophenolic acid

Generic Name
Mycophenolic acid
Brand Names
Myfortic
Drug Type
Small Molecule
Chemical Formula
C17H20O6
CAS Number
24280-93-1
Unique Ingredient Identifier
HU9DX48N0T
Background

Mycophenolic acid is a potent immunosuppressant agent that inhibits de novo purine biosynthesis. It was derived from Penicillium stoloniferum, and has also shown antibacterial, antifungal and antiviral properties.. Mycophenolic acid is used in immunosuppressive regimens as part of a triple therapy that includes a calcineurin inhibitor (ciclosporin or tacrolimus) and prednisolone. This regimen can be used in place of the older anti-proliferative azathioprine due to its stronger immunosuppressive potency. However, mycophenolic acid treatment is more expensive and requires therapeutic drug monitoring to optimize efficacy and minimize toxicity. Mycophenolic acid is available as enteric-coated tablets of delayed-release, in an effort to improve upper gastrointestinal adverse events by delaying mycophenolic acid release until it reaches the small intestine. Mycophenolate mofetil, a prodrug of mycophenolic acid, is also prescribed to transplant recipients to prevent organ rejection.

Indication

Mycophenolic acid is an antimetabolite immunosuppressant indicated for prophylaxis of organ rejection in adult patients receiving kidney transplants and in pediatric patients at least 5 years of age and older who are at least 6 months post kidney transplant. Mycophenolic acid is used in combination with cyclosporine and corticosteroids.

Associated Conditions
Kidney Transplant Rejection

Optimize Immunosuppressive Therapy Using Everolimus and Low-dose Calcineurin Inhibitors in Heart Transplant Patients in Korea

Phase 4
Not yet recruiting
Conditions
Heart Transplant
Interventions
First Posted Date
2025-04-24
Last Posted Date
2025-04-24
Lead Sponsor
Chong Kun Dang Pharmaceutical
Target Recruit Count
140
Registration Number
NCT06942156
Locations
🇰🇷

Samsung Medical Center, Seoul, Korea, Republic of

Optimizing GVHD Prophylaxis After Allogeneic Hematopoietic Cell Transplantation

Phase 2
Not yet recruiting
Conditions
Hematological Malignancies
Graft-versus-Host Disease (GVHD)
Interventions
First Posted Date
2025-01-29
Last Posted Date
2025-04-24
Lead Sponsor
University of Nebraska
Target Recruit Count
126
Registration Number
NCT06799195
Locations
🇺🇸

University of Nebraska Medical Center, Omaha, Nebraska, United States

Which of the Commonly Available and Approved Drugs in Addition to Standard of Care Can Significantly Improve the Slope of Estimated Glomerular Filtration Rate At Two Years When Compared to Standard of Care Alone in South-Asian Kidney Biopsy-proven Adult (≥18 Years) Primary IgA Nephropathy?

Phase 4
Not yet recruiting
Conditions
IgA Nephropathy
Renal Insufficiency, Chronic
IgA Vasculitis
IGA Glomerulonephritis
Interventions
Drug: Non-steroidal mineralocorticoid receptor antagonist and SoC
Drug: SoC defined as maximal labelled or tolerated dose of angiotensin-converting enzyme inhibitor/ angiotensin receptor blocker (ACEi/ARB) & steady dose of sodium-glucose cotransporter-2 inhibitor (SGLT2i)
Drug: Oral prednisolone and SoC
Drug: Gut-directed budesonide and SoC
First Posted Date
2024-11-06
Last Posted Date
2024-11-06
Lead Sponsor
Christian Medical College, Vellore, India
Target Recruit Count
585
Registration Number
NCT06676384
Locations
🇮🇳

Muljibhai Patel Urological Hospital, Nadiad, Gujarat, India

🇮🇳

JSS Medical College, Mysuru, Karnataka, India

🇮🇳

Kasturba Medical College, Manipal, Udupi, Karnataka, India

and more 9 locations

Induction of Remission in Autoimmune Hepatitis With Azathioprine vs. MMF

First Posted Date
2024-10-21
Last Posted Date
2024-11-07
Lead Sponsor
Institute of Liver and Biliary Sciences, India
Target Recruit Count
108
Registration Number
NCT06650124

A Study of Tacrolimus/Methotrexate/Ruxolitinib Versus Post-Transplant Cyclophosphamide/Tacrolimus/Mycophenolate Mofetil in Non-Myeloablative/Reduced Intensity Conditioning Allogeneic Peripheral Blood Stem Cell Transplantation (BMT CTN 2203)

First Posted Date
2024-09-26
Last Posted Date
2025-05-15
Lead Sponsor
Incyte Corporation
Target Recruit Count
572
Registration Number
NCT06615050
Locations
🇺🇸

University of Pennsylvania, Philadelphia, Pennsylvania, United States

🇺🇸

Blood and Marrow Transplant Group of Georgia, Atlanta, Georgia, United States

🇺🇸

Karmanos Cancer Institute, Detroit, Michigan, United States

and more 2 locations

Reduced Immunosuppression in Older Renal Transplant Recipients With Trugraf® Monitoring (RIOT Trial): A Prospective, Randomized, Multicenter Trial.

Phase 4
Not yet recruiting
Conditions
Kidney Transplantation
Mycophenolate Mofetil
Interventions
First Posted Date
2024-08-23
Last Posted Date
2025-02-13
Lead Sponsor
Mayo Clinic
Target Recruit Count
350
Registration Number
NCT06568549
Locations
🇺🇸

Mayo Clinic, Rochester, Minnesota, United States

A Study to Evaluate IMC-002 in Neuromyelitis Optica Spectrum Disorder (NMOSD) Patients

Phase 1
Not yet recruiting
Conditions
Neuromyelitis Optica Spectrum Disorder (NMOSD)
Interventions
First Posted Date
2024-08-16
Last Posted Date
2024-08-16
Lead Sponsor
ImmuneCare Biopharmaceuticals (Shanghai) Co., Ltd.
Target Recruit Count
116
Registration Number
NCT06557174

Mycophenolate-Based Therapy for Kidney Transplant Recipients Without HLA-DQ Mismatch

First Posted Date
2024-07-10
Last Posted Date
2024-08-21
Lead Sponsor
University Hospital, Antwerp
Target Recruit Count
20
Registration Number
NCT06493526
Locations
🇧🇪

University Hospital Antwerp, Edegem, Antwerp, Belgium

Belatacept in Heart Transplantation

Phase 2
Recruiting
Conditions
Heart Transplant
Interventions
First Posted Date
2024-06-27
Last Posted Date
2025-02-11
Lead Sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
Target Recruit Count
66
Registration Number
NCT06478017
Locations
🇺🇸

Cedars Sinai Heart Institute/ Cedars Sinai Medical (Site # 71146), Los Angeles, California, United States

🇺🇸

Tampa General Hospital (Site # 71150), Tampa, Florida, United States

🇺🇸

NYU Langone Health (Site # 71177), New York, New York, United States

and more 1 locations

A Dose Escalation Study of TCD601 Compared to ATG in de Novo Renal Transplantation

Phase 2
Completed
Conditions
Kidney Transplantation
Interventions
First Posted Date
2024-04-15
Last Posted Date
2025-01-29
Lead Sponsor
ITB-Med LLC
Target Recruit Count
33
Registration Number
NCT06365437
Locations
🇸🇪

Skåne University Hospital, Malmö, Sweden

🇸🇪

Sahlgrenska University Hospital, Göteborg, Sweden

🇦🇹

Innsbruck Medical University, Innsbruck, Austria

and more 4 locations
© Copyright 2025. All Rights Reserved by MedPath